A noble milestone in the field is the FDA approval of Casgevy, the first CRISPR-based cell therapy, which employs CRISPR-Cas9 to edit BCL11A in hematopoietic stem cells for treating hematologic disorders. Here, BCL11A is linked to hematologic disorder.